Affinity of Muscarinic Receptor Antagonists for Three Putative Muscarinic Receptor Binding Sites

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1989 Feb 1

PMID 2924085

Citations 22

Authors

R E Delmendo

A D Michel

R L Whiting

Affiliations

Soon will be listed here.

Abstract

1. A range of muscarinic receptor antagonists were examined for affinity at the M1 muscarinic binding site, present in rat cerebrocortical membranes and the M2 muscarinic binding sites of rat cardiac and submaxillary gland membranes. 2. The results obtained were consistent with the presence of three classes of muscarinic binding site. 3. Both the M1 binding site, labelled by [3H]-pirenzepine ([3H]-Pir) in rat cerebrocortical membranes, and the M2 gland binding site, labelled by [3H]-N-methyl scopolamine ([3H]-NMS) in rat submaxillary gland membranes, displayed higher affinity for pirenzepine, dicyclomine, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) and cyclohexylphenyl (2-piperidinoethyl) silanol (CPPS) than did the M2 binding sites of cardiac membranes labelled by [3H]-NMS. 4. The M2 cardiac sites displayed higher affinity for methoctramine, himbacine and AF-DX 116 than did either the M1 binding site of cerebrocortical membranes or the M2 gland binding site present in rat submaxillary gland membranes. 5. The M1 and M2 gland binding sites could only be distinguished by considering the absolute affinity of compounds for these two sites. Thus, all compounds, with the exception of 4-DAMP, displayed between a 2 and 8 fold higher affinity for the M1 than for the M2 gland binding site. There were no antagonists with higher M2 gland than M1 affinity.

Citing Articles

Possible Tracheal Relaxant and Antimicrobial Effects of the Essential Oil of Ethiopian Thyme Species ( Hochst. ex Benth.): A Multiple Mechanistic Approach.

Ur Rehman N, Ansari M, Haile T, Karim A, Abujheisha K, Ahamad S Front Pharmacol. 2021; 12:615228.

PMID: 33883992 PMC: 8053776. DOI: 10.3389/fphar.2021.615228.

Evaluation of bronchodialatory and antimicrobial activities of A multi-mechanistic approach.

Ansari M, Ur Rehman N, Karim A, Bahta T, Abujheisha K, Ahamad S Saudi Pharm J. 2020; 28(3):281-289.

PMID: 32194329 PMC: 7078568. DOI: 10.1016/j.jsps.2020.01.007.

Pharmacological Basis for the Medicinal Use of Lepidium sativum in Airways Disorders.

Rehman N, Khan A, Alkharfy K, Gilani A Evid Based Complement Alternat Med. 2012; 2012:596524.

PMID: 22291849 PMC: 3265128. DOI: 10.1155/2012/596524.

Insights into mechanisms underlying the gut and airways modulatory effects of Swertia chirata.

Khan A, Rahim A, Iqbal Z, Gilani A J Nat Med. 2011; 66(1):140-8.

PMID: 21792726 DOI: 10.1007/s11418-011-0566-2.

Analgesic and antineuropathic drugs acting through central cholinergic mechanisms.

Bartolini A, Di Cesare Mannelli L, Ghelardini C Recent Pat CNS Drug Discov. 2011; 6(2):119-40.

PMID: 21585331 PMC: 3182079. DOI: 10.2174/157488911795933901.

References

Cheng Y, Prusoff W . Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22(23):3099-108. DOI: 10.1016/0006-2952(73)90196-2. View

RIKER Jr W, WESCOE W . The pharmacology of Flaxedil, with observations on certain analogs. Ann N Y Acad Sci. 1951; 54(3):373-94. DOI: 10.1111/j.1749-6632.1951.tb39932.x. View

Barlow R, Berry K, Glenton P, Nilolaou N, Soh K . A comparison of affinity constants for muscarine-sensitive acetylcholine receptors in guinea-pig atrial pacemaker cells at 29 degrees C and in ileum at 29 degrees C and 37 degrees C. Br J Pharmacol. 1976; 58(4):613-20. PMC: 1667484. DOI: 10.1111/j.1476-5381.1976.tb08631.x. View

Birdsall N, BURGEN A, Hulme E, Wells J . The effects of ions on the binding of agonists and antagonists to muscarinic receptors. Br J Pharmacol. 1979; 67(3):371-7. PMC: 2043948. DOI: 10.1111/j.1476-5381.1979.tb08690.x. View

Hammer R, Berrie C, Birdsall N, BURGEN A, Hulme E . Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature. 1980; 283(5742):90-2. DOI: 10.1038/283090a0. View

Munson P, Rodbard D . Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980; 107(1):220-39. DOI: 10.1016/0003-2697(80)90515-1. View

Brown D, Forward A, Marsh S . Antagonist discrimination between ganglionic and ileal muscarinic receptors. Br J Pharmacol. 1980; 71(2):362-4. PMC: 2044477. DOI: 10.1111/j.1476-5381.1980.tb10948.x. View

Cheung Y, Barnett D, Nahorski S . [3H]Rauwolscine and [3H]yohimbine binding to rat cerebral and human platelet membranes: possible heterogeneity of alpha 2-adrenoceptors. Eur J Pharmacol. 1982; 84(1-2):79-85. DOI: 10.1016/0014-2999(82)90159-5. View

Hammer R, Giachetti A . Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci. 1982; 31(26):2991-8. DOI: 10.1016/0024-3205(82)90066-2. View

10.

Gil D, Wolfe B . Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase. J Pharmacol Exp Ther. 1985; 232(3):608-16. View

11.

Clague R, Eglen R, Strachan A, Whiting R . Action of agonists and antagonists at muscarinic receptors present on ileum and atria in vitro. Br J Pharmacol. 1985; 86(1):163-70. PMC: 1916877. DOI: 10.1111/j.1476-5381.1985.tb09446.x. View

12.

Gilani H, COBBIN L . The cardio-selectivity of himbacine: a muscarine receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 1986; 332(1):16-20. DOI: 10.1007/BF00633191. View

13.

Hammer R, Giraldo E, Schiavi G, MONFERINI E, Ladinsky H . Binding profile of a novel cardioselective muscarine receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. Life Sci. 1986; 38(18):1653-62. DOI: 10.1016/0024-3205(86)90409-1. View

14.

Giachetti A, Micheletti R, Montagna E . Cardioselective profile of AF-DX 116, a muscarine M2 receptor antagonist. Life Sci. 1986; 38(18):1663-72. DOI: 10.1016/0024-3205(86)90410-8. View

15.

BURGEN A . The effect of ionic strength on cardiac muscarinic receptors. Br J Pharmacol. 1986; 88(2):451-5. PMC: 1916837. DOI: 10.1111/j.1476-5381.1986.tb10223.x. View

16.

Melchiorre C, Cassinelli A, Quaglia W . Differential blockade of muscarinic receptor subtypes by polymethylene tetraamines. Novel class of selective antagonists of cardiac M-2 muscarinic receptors. J Med Chem. 1987; 30(1):201-4. DOI: 10.1021/jm00384a034. View

17.

Doods H, Mathy M, Davidesko D, van Charldorp K, de Jonge A, van Zwieten P . Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther. 1987; 242(1):257-62. View

18.

Clark A, Mitchelson F . The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol. 1976; 58(3):323-31. PMC: 1667582. DOI: 10.1111/j.1476-5381.1976.tb07708.x. View